Last reviewed · How we verify
Paracetamol (500 mg) tablets
Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Mild to moderate pain, Fever reduction.
At a glance
| Generic name | Paracetamol (500 mg) tablets |
|---|---|
| Sponsor | Novartis |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX), primarily in central nervous system |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Paracetamol (acetaminophen) works primarily by inhibiting cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering pain perception and body temperature set point. Unlike NSAIDs, it has minimal peripheral anti-inflammatory effects and does not significantly inhibit COX in peripheral tissues, making it gentler on the gastrointestinal tract and cardiovascular system.
Approved indications
- Mild to moderate pain
- Fever reduction
Common side effects
- Hepatotoxicity (at overdose)
- Rash
- Nausea
- Abdominal pain
Key clinical trials
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- PARASTOP - Paracetamol With Strong Opioids (PHASE3)
- Reduced Opioid Prescription After Laparoscopic Hysterectomy (NA)
- Effect of Estrogen Treatment on Drug Metabolism and Transport (PHASE4)
- Opioid Use After Laparoscopic Salpingectomy (PHASE4)
- Evaluation of the Pain Relief Effect of Battlefield Acupuncture on Patients With Chronic Low Back Pain Due to Lumbar Spine Degeneration. (NA)
- NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL) (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paracetamol (500 mg) tablets CI brief — competitive landscape report
- Paracetamol (500 mg) tablets updates RSS · CI watch RSS
- Novartis portfolio CI